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Abstract
Background: Cancer stem cell (CSC) hypothesis postulates that tumors are maintained by a self-renewing CSC
population that is also capable of differentiating into non-self-renewing cell populations that constitute the bulk of
tumor. Stem cells renewal and differentiation can be directly influenced by the oxygen levels of determined
tissues, probably by the reduction of oxidative DNA damage in hypoxic regions, thus leading to a friendlier
microenvironment, regarding to clonal expansion and for resistance to chemotherapeutic regimens. Furthermore,
there have been strong data indicating a pivotal role of hypoxic niche in cancer stem cells development. There are
evidence that hypoxia could drive the maintenance of CSC, via HIF-1a expression, but it still to be determined
whether hypoxia markers are expressed in breast tumors presenting CD44+CD24-/low immunophenotype.
Methods: Immunohistochemical analysis of CD44+CD24-/low expression and its relationship with hypoxia markers
and clinical outcome were evaluated in 253 samples of breast ductal carcinomas. Double-immunolabeling was
performed using EnVision Doublestain System (Dako, Carpinteria, CA, USA). Slides were then scanned into high-
resolution images using Aperio ScanScope XT and then, visualized in the software Image Scope (Aperio, Vista, CA,
USA).
Results: In univariate analysis, CD44+CD24-/low expression showed association with death due to breast cancer (p =
0.035). Breast tumors expressing CD44+CD24-/low immunophenotype showed relationship with HIF-1a (p = 0.039)
and negativity for HER-2 (p = 0.013).
Conclusion: Considering that there are strong evidences that the fraction of a tumour considered to be cancer
stem cells is plastic depending upon microenvironmental signals, our findings provide further evidence that
hypoxia might be related to the worse prognosis found in CD44+CD24-/low positive breast tumors.
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Background
The cancer stem cell (CSC) hypothesis postulates that
tumors are maintained by a self-renewing CSC popula-
tion that is also capable of differentiating into non-self-
renewing cell populations that constitute the bulk of the
tumor [1]. The first insight indicating a role of breast
cancer stem cells (BCSC) in breast carcinogenesis was
demonstrated by the study of Al-Hajj and co-workers,
where Lin-CD44+CD24-/low cells injected into the mam-
mary fat pad of non-obese diabetic/severed combined
immunodeficient (NOD/SCID) mice were able to form
palpable tumors, even with just a few hundred of cells
being transplanted. Another interesting observation in
the same study was the fact that Lin-CD44+CD24-/low
cells were not only able to give origin to additional Lin-
CD44+CD24-/low cells, but also generated phenotypically
distinct cells, indicating that BCSC could generate an
homogeneous population of non-tumorigenic cells,
besides the generation of new BCSC [2].
Stem cells renewal and differentiation can be directly
influenced by the oxygen levels of determined tissues,
probably by the reduction of oxidative DNA damage in
hypoxic regions, thus leading to a friendlier microenvir-
onment, regarding to clonal expansion and for
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resistance to chemotherapeutic regimens [3]. Further-
more, there have been strong data indicating a pivotal
role of hypoxic niche in cancer stem cells development,
especially in glioblastomas [4,5].
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric
complex consisting of a and b subunits. There are 3
human HIF-a genes (HIF-1a, HIF-2a, and HIF-3a) that
are oxygen sensitive, although only the first 2 have been
extensively studied. HIF-1a is the best characterized and
the most ubiquitously expressed, functioning as a regu-
lator of oxygen homeostasis in many cell types [6]. High
levels of HIF-1a have been correlated with tumor pro-
gression and poor prognosis in patients with brain, non-
small-cell lung, breast, ovarian, uterine, and cervical can-
cers [7].
Hypoxia-regulated protein carbonic anhydrase IX
(CAIX) has been studied in several tumors and its expres-
sion has been related with clinical outcome [8-10]. CAIX
regulates tissue pH and is induced by hypoxia, mainly in
an HIF-1-dependent manner, playing an important role
on maintenance of hypoxia state in solid tumors [10].
Nevertheless, the relationship between CAIX expression
and CSCs in breast cancer was not addressed.
The relationship between hypoxia markers and CD44
+CD24-/low immunophenotype in breast tumors still
poorly understood. Our study aims to investigate the
prognostic impact of CD44+CD24-/low immunoexpres-
sion in breast cancer. Further, we hope to understand
its relationships with hypoxia markers (HIF-1a and
CAIX), clinical outcome, clinicopathological findings
and immunohistochemical prognostic markers, including
estrogen receptor (ER), progesterone receptor (RP),
human epidermal growth factor receptor-2 (HER-2),
breast cancer gene 1 (BRCA1), the proliferation marker
Ki67 and p53.
Methods
Patients and clinicopathologic information
A total of 300 cases of invasive ductal carcinoma of the
female breast diagnosed between 1994 and 2004 were
retrieved from the files of the Department of Pathology
of the General Hospital of Ribeirao Preto School of
Medicine, University of Sao Paulo, Brazil. From the
medical registers, the following information was
retrieved: age, menopausal status, tumor size, metastasis
to regional lymph nodes, recurrence, distant metastasis,
death, disease-specific survival and disease-free survival.
Patients who received antiestrogen or radion and/or
chemotherapy had been previously excluded from the
study. Disease-specific survival (DSS) was defined as the
number of months from diagnosis to the time of death
due to breast cancer and disease-free survival (DFS) was
defined as the time from diagnosis to the occurrence of
local recurrence or metastasis.
For each case, each available hematoxylin and eosin
(H&E)-stained section was reviewed to confirm the diag-
nosis of invasive ductal carcinoma and to delimitate a
representative block for tissue microarray construction.
Cases without complete data and/or sufficient material
were excluded from the study. The cases were graded
according to the current guidelines of the Scarff-Bloom
& Richardson grading system modified by Elston & Ellis
[11]. None of patients had received any treatment before
the biopsy procedure. The study protocol conformed to
the ethical guidelines of the 1975 Declaration of Hel-
sinki and was approved by the local Ethics Committee.
Tissue microarray (TMA)
The hematoxylin and eosin (H&E) slides were reviewed
by two experienced pathologists (ARS and FRV) to deli-
mit the most significant area of each tumor. This region
was then selected to the construction of tissue microar-
ray (TMA) paraffin block. For TMA block construction,
core biopsies (diameter, 1 mm) were punched from the
selected regions of each of the 300 donor paraffin blocks
and arrayed into a new recipient paraffin block using a
Manual Tissue Arrayer I (Beecher Instruments, Silver
Spring, USA). Three-μm-thick sections were cut from
TMA paraffin block using the Paraffin tape-transfer sys-
tem (Instrumedics, Saint Louis, USA). One section was
stained with H&E to confirm the presence of the tumor
by light microscopy. Immunohistochemistry was carried
out on two slides at different depth levels to increase
the accuracy and strength of the array-based data.
Immunohistochemistry
Tissue samples had been routinely fixed in 4% neutral
formalin and embedded in paraffin. Immunohistochem-
ical staining was developed using the Novolink™ Max
Polymer Detection System (Novocastra, Newcastle Upon
Tyne, UK). Briefly, paraffin sections were de-waxed in
xylene and rehydrated through a series of graded alco-
hols. Endogenous peroxidase activity was blocked for 30
min in a solution containing 0.3% of hydrogen peroxide
in order to block non-specific immunoassaying. The sec-
tions were then placed in 10 mM citrate buffer and sub-
mitted to heat retrieval using a vapor lock for 40
minutes. After antigen retrieval, specimens were allowed
to cool for 30 minutes at room temperature, and then
incubated at 4°C overnight with primary antibody. The
dilution and source of the primary antibodies used in
this study were: CD44 (1:50, clone DF1485, Novocastra,
Newcastle upon Tyne, UK), CD24 (1:50, clone SN3b,
Thermo Scientific, Fremont, CA, USA), HIF-1a (1:50,
monoclonal, Abcam, Cambridge, UK), CAIX (1:100),
p53 (1:50, clone DO-7, Novocastra, Newcastle upon
Tyne, UK), estrogen receptor (ER) (1:100 clone 6F11,
Novocastra, Newcastle upon Tyne, UK), progesterone
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receptor (PR) (1:100, clone 16, Novocastra, Newcastle
upon Tyne, UK), and c-erbB-2 (1:100, clone CB11,
Novocastra, Newcastle upon Tyne). After the overnight
incubation with the primary antibody, the slides were
incubated with post primary solution for 30 minutes
and then incubated with the polymer for 30 minutes
(both provided by the Novolink™ Max Polymer Detec-
tion System). The reaction was stained with diamino-
benzidine (DAB) followed by hematoxylin
counterstaining. The slides were then dehydrated in an
ethanol series and mounted with Permount (Fischer,
Fairlawn, NJ). Double-immunolabeling was performed
according to the manufacturer’s instructions (EnVision
Doublestain System, Dako, Carpinteria, CA, USA).
CD44 was stained with DAB (brown), and CD24 was
stained with fast red (red) (Figure 1)
Glioblastoma cases were used as positive control for
HIF-1a. Cases of invasive ductal carcinoma previously
known to be positive for CD24, CAIX, ER, PR, p53, and
HER-2 were used as positive controls for those markers.
Negative controls for immunostaining were prepared by
omission of the primary antibody.
Image analysis
CD44 was identified as brown and CD24 as red mem-
brane staining. Cells with brown color staining without
much interference from red color were identified as
CD44+/CD24-/low tumor cells, whereas cells with
intense red staining in the absence of brown color were
characterized as CD44-/CD24+ tumor cells. The slides
were then scanned into high-resolution images using
Aperio ScanScope XT (Aperio, Vista, CA, USA). The
images were then visualized in the software Image
Scope (Aperio, Vista, CA, USA).
To define the cut-off point for CD44 and CD24 we
have followed the criteria of Giatromanolaki and colla-
borators [12]. CD44 and CD24 positive cases were
considered as those which had more than 10% of
stained membranes. For HIF-1a and CAIX we followed
the criteria of Chen et al [13]. Were considered positive
to HIF-1a cases with more than 1% of nuclear staining
and, to CAIX, cases with more than 1% of membranous
staining. The cases in which more than 10% of neoplas-
tic cells stained for Ki67 (nuclear staining) were consid-
ered highly proliferative. The cases were interpreted as
ER, PR, BRCA1 and p53 positive if more than 10% of
the neoplastic cells showed nuclear staining [11].
HER-2 immunoexpression was scored according to
current guidelines [15]. For statistical purposes, carcino-
mas with score 0 or 1+ were considered negative; and
carcinomas with score 3+ were considered positive.
Cases with HER-2 scored as 2+ were submitted to chro-
mogenic in situ hybridization (CISH) for HER2.
All immunostains and CISH slides were independently
analyzed and scored by two experienced pathologists
(ARS and FRV). Whenever a discrepancy between the
readings occurred, the two pathologists discussed the
case in a multi-head microscope and reached a consen-
sus agreement for the final scoring.
Chromogenic in situ hybridization (CISH)
Sections (3 μm) were cut from the original paraffin
blocks in the cases in which the HER2 was graded as 2+
by the immunohistochemical method. The ZytoDot 2C
SPEC HER2/CEN 17 probe kit (Zytovision, Bremerha-
ven, Germany) was used for the detection of the human
HER2 gene and alpha-satellites of chromosome 17. All
procedures were performed step by step according to
the manufacturer’s instructions. Using this kit, two
green (HER2) and two red (CEN 17) signals are
expected in a normal interphase nucleus. HER2 was
considered amplified when the HER2/CEN 17 ratio was
≥ 2 on average for 60 cells [14]. Only the cases scored
as 2+ by the immunohistochemical method in which the
Figure 1 Double immunostaining showing CD44 (brown) and CD24 (red). A) Immunofenotype CD44-CD24+. B) Immunofenotype CD44
+CD24+ (for means of comparison).
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HER2 was amplified on CISH analysis were considered
positive.
Statistical analysis
SPSS Statistics 18.0 (Chicago, IL, USA) was used to per-
form statistical analyses and tests. The relationships
between CD44+CD24-/low expression, immunohisto-
chemical findings and clinicopathological features were
tested with cross tables applying the c2 (three or more
variables) or Fisher tests (two variables), and all tests
were 2-tailed. The Kaplan-Meier curves using the log-
rank test were used to estimate and compare disease-
specific survival, disease-free survival and metastasis-free
survival. In order to observe the independent prognostic
value of the variables we performed a Cox Proportional
Hazards Model. A p-value of < 0.05 was considered
significant.
Results
Demographics of the patients and tumor characteristics
Of the 300 cases initially selected to this study 253
had all clinical data and sufficient material for tissue
microarray construction and immunohistochemistry
analysis.
The relationship between CD44+CD24-/low immuno-
phenotype expression and clinicopathological findings
is summarized in Table 1. The age of the patients ran-
ged between 19 to 91 years (mean, 56,19 years). All
patients were female. Ninety two patients (35%) were
premenopausal and 171 were post-menopausal (65%).
All tumors were classified as invasive ductal carcino-
mas (ICDs), with sizes ranging from 1 to 18 cm (med-
ian, 4.45 cm). The tumors were classified as grade 1
(97 [36.9%]), grade 2 (126 [47.9%]) and grade 3 (40
[15.2%]). Seventy three patients (28.9%) had tumors
with less than 2 cm, 105 had tumors between 2 and 5
cm (41.5%) and 75 had tumors larger than 5 cm
(29.6%). One hundred and twenty three (46.8%)
patients had no metastatic lymph nodes, while 140
(53.2%) were lymph node positive. According to the
Clinical Staging System, created by the American Joint
Committee on Cancer (Singletary et al., 2003), thirty
five (13.3%) were classified as stage I, 64 (24.3%) were
IIa, 55 (20.9%) were IIb, 27 (10.3%) were IIIa, 66 were
IIIb (25.1%), and 16 were IV (6.1%). Distant metastasis
occurred in 81 (30.8%) patients and 178 (67.7%) died
due to breast cancer.
CD44+CD24-/low expression showed association with
death due to breast cancer (p = 0.035) but not with age
(p = 0.789), menopausal status (p = 0.131), clinical stage
(p = 0.219), histological grade (p = 0.319), lymph node
status (p = 0.895), recurrence (p = 1.000), or distant
metastasis (p = 0.479).
Immunohistochemical results
The relationship between CD44+CD24-/low immunophe-
notype expression and immunohistochemical findings is
summarized in Table 2. In our study, we found a CD44
+CD24-/low phenotype in 92 of 253 cases (35%) (Figure
1). The positivity rate for ER, PR, HER-2, and p53 were,
respectively, 63.6% (161 cases), 59.3% (150 cases), 19.8%
(50 cases) and 64% (162 cases). The positivity rate for
the hypoxia markers used in this study was 55 cases
(21.7%) for HIF-1a, 67 cases (26.5%) for CAIX
immunoexpression.
CD44+CD24-/low immunophenotype showed relation-
ships with HIF-1a (p = 0.039) and negativity for HER-2
(p = 0.013). There were no relationships with the
expression levels of estrogen (p = 0.340) and progester-
one (p = 0.141) receptors, Ki67 (p = 0.410), CAIX (p =
0.551) and p53 (p = 0.786) (Table 1).
CD44+CD24-/low immunophenotype and survival
The follow up period for the patients in the study ran-
ged from 1 to 164 months, and the mean survival time
was 66.96 months. Using Kaplan-Meier survival analysis
with the log-rank test, we found significantly worse dis-
ease-specific survival (p = 0.035) for the CD44+CD24-/
low cases (Figure 2). No differences were found in dis-
ease-free survival (p = 0.720) (Figure 3). In multivariate
analysis, CD44+CD24-/low expression was not an inde-
pendent prognostic factor.
Discussion
In this study, we determined the relationships between
CD44+CD24-/low phenotype and hypoxia markers, HIF-
1a and CAIX, and classical prognostic factors in breast
pathology, including clinicopathological features and the
expression of immunohistochemical markers of prog-
nostic significance (HER2 status, p53 expression and
hormonal status). To the best of our knowledge this is
the first study demonstrating an association between
hypoxia markers and the CD44+CD24-/low phenotype in
a large series of breast invasive ductal carcinomas, by
immunohistochemistry.
Similar to the results of Honeth and co-workers, we
found 35% of cases showing CD44+CD24-/low immuno-
phenotype, suggesting that not all breast tumors contain
cells with this phenotype, as described by Al-Hajj in
2003 [16,2].
Since the discovery of the high capacity of generating
new tumor cells by mammary CD44+CD24-/low cells,
this phenotype are associated with worse survival and
aggressive behavior [17]. Sheridan and co-workers
showed that CD44+CD24-/low phenotype is associated
with enhanced invasive properties and elevated expres-
sion of genes involved in invasion [18]. Further, the
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Table 1 Relationship between clinical and pathological features and breast carcinomas expressing the
immunophenotype CD44+CD24-/low and carcinomas that do not express this immunophenotype
Feature CD44+CD24-/low positive CD44+CD24-/low negative p-value
Age (years) 0.789
< 50 38 66
> 50 51 98
Menopausal status 0.131
Pre 38 53
Post 51 111
Tumor size (cm) 0.837
< 2 24 49
2-5 39 66
> 5 26 49
Bloom & Richardson 0.319
I 28 66
II 48 73
III 13 25
Clinical Staging 0.219
I 12 21
IIa 21 40
IIb 19 34
IIIa 6 20
IIIb 22 44
IV 9 5
Recurrence 1.000
Yes 11 21
No 78 143
Lymph node status 0.895
Pos 47 89
Neg 42 75
Distant metastasis 0.479
Yes 30 48
No 59 116
Death 0.035*
Yes 37 46
No 52 118
*Statistically significant.
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CD44+CD24-/low cell population was related with poor
prognosis, although not in all studies [12]. In the study
of Mylona and cols., the CD44+CD24-/low phenotype
was emerged as a poor prognostic indicator, within the
group of grade II tumors [19]. Furthermore, clinical stu-
dies indicate that CD44+/CD24- tumor-initiating cells
express an invasive gene signature and may be asso-
ciated with distant metastases [20-22]. Although the
mechanisms of this aggressive behavior are not fully
understood, it is now accepted that the generation of
different subclones provides tools to tumorigenic cells
proliferation and invasion abilities, leading to metastasis
and insensitivity to classical treatments [17,23].
Here we demonstrated that CD44+CD24-/low breast
tumors show an association with HIF-1a status, but not
with CAIX. Recent studies have shed light in the
relationship between cancer stem cells and tumor
hypoxia. There are strong evidences that the fraction of
a tumour considered to be cancer stem cells is plastic
depending upon microenvironmental signals such as
hypoxia [24]. Soeda and collaborators demonstrated that
culture in hypoxia and activation of HIF-1a expands the
sub-population of cells positive for markers associated
with a more stem-like phenotype, such as CD133 and
CD44 (25). A study from Pahlman and colleagues has
also shown that hypoxia in neuroblastoma cells can alter
gene expression to that of a more immature pheno-
type.26 There are recently published data demonstrating
this critical role of hypoxia in maintaining the stem-like
fraction of cancer cells [27,4,28].
Table 2 Relationship between immunohistochemical
features and breast carcinomas expressing CD44+CD24-/
low immunophenotype and carcinomas that do not
express this immunophenotype
Feature CD44+CD24-/low
positive
CD44+CD24-/low
negative
p-
value
RE 0.340
Pos 53 108
Neg 36 56
RP 0.141
Pos 47 103
Neg 42 61
p53 0.786
Pos 56 106
Neg 33 58
HER-2 0.013*
Pos 10 40
Neg 79 124
Ki67 0.410
Pos 34 54
Neg 55 110
HIF-1a 0.039*
Pos 26 29
Neg 63 135
CAIX 0.551
Pos 26 41
Neg 63 123
*Statistically significant.
Figure 2 Univariate analysis of the prognostic impact of CD44
+CD24-/low status on disease-specific survival of breast cancer
patients. Using Kaplan Mayer table followed by log-rank test.
Figure 3 Univariate analysis of the prognostic impact of CD44
+CD24-/low status on disease-free survival of breast cancer
patients. Using Kaplan Mayer table followed by log-rank test.
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Low oxygen levels promote maintenance of embryonic
stem cell pluripotent potential and block differentiation
[29]. In a recent study, Bar and co-workers showed that
gliobastoma neurosphere cell lines and freshly resected
tumors respond to hypoxia by an increase in cancer
stem cell marker CD133 expression. These neurospheres
also exhibited a significant increase in clonogenic capa-
city, after 12 and 24 hours of hypoxia. According to the
authors, HIF-1a alone can mediate the majority of
hypoxic effects in gliobastoma neurospheres, indicating
a pivotal role of HIF-1a in clonal expansion of cancer
stem cells [5].
Further findings indicate that more than co-acting in
cancer stem cell maintenance, hypoxia could drive the
maintenance of a cancer stem cell niche, with a strong
participation of HIF-1a. Heddleston and colleagues
showed that non-stem glioma cells cultured under
hypoxic conditions had twice the rate of formation of
neurospheres, compared to cells in normoxia, suggesting
that a hypoxic microenvironment plays a pivotal role in
promoting and maintaining the ability of self-renew in
stem-like cells, and even conferring self-renewal capabil-
ity to non-stem cell population [4].
Our finding that HIF-1a is related to CD44+CD24-/low
immunphenotype in breast ductal carcinomas could
indicate that a maintained hypoxia state in breast cancer
could facilitate the maintenance of cancer stem cells in
these tumors, corroborating the finding that CD44
+CD24-/low positive tumors have a worse prognosis
when compared to non- CD44+CD24-/low tumors. The
association between negativity to CD44+CD24-/low
immunophenotype and negativity to HIF-1a and CAIX
expression could, at least in part, explain the better sur-
vival of this group of patients, and also the worst prog-
nosis associates with CD44+CD24-/low cases.
We also found an association between CD44+CD24-/
low phenotype and HER-2 status. Patients lacking CD44
+CD24-/low phenotype showed negativity to HER-2
immunohistochemycal expression. Recently, Oliveras-
Ferraros and co-workers had demonstrated that CD44
+CD24-/low cells could be important in de novo resis-
tance to direct HER inhibitors such as trastuzumab
(Herceptin©), a HER-2 directed antibody, and other stu-
dies suggest that the clinical efficacy of trastuzumab
may relate to its ability to directly target the CSC popu-
lation in HER-2-amplified tumors [30,22,23].
In fact HER-2 positive tumors constitute a group with
a worse prognosis, when compared to tumors lacking
HER-2 expression. The relationship between non- CD44
+CD24-/low tumors and negativity to HER-2 could
explain the better prognosis found in this group of
patients.
Conclusion
The differential expression of hypoxia marker HIF-1a in
CD44+CD24-/low tumors is in accordance with the cur-
rent knowledge regarding relationship between microen-
vironmental factor such as hypoxia or anoxia states with
maintenance and propagation of cancer stem cells.
Taken together with the differential expression of HER-
2, these findings provides further evidence on the worse
prognosis found in CD44+CD24-/low positive tumors,
and might contribute to the more aggressive behavior of
these neoplasms. Furthermore, the relationship between
hypoxia markers in tumors presenting CSC niche needs
to be better understood, and further studies are needed
to clarify the molecular basis of these hypoxic CSC-
tumors.
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